Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00018642|
Recruitment Status : Completed
First Posted : July 5, 2001
Last Update Posted : January 21, 2009
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Schizoaffective Disorder||Drug: quetiapine Drug: haloperidol decanoate||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia|
|Study Start Date :||April 1997|
|Study Completion Date :||March 2002|
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 60 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
- Between the ages 18-60.
- A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms.
- Organic brain disease.
- Mental Retardation
- Chronic medical illness which would make antipsychotic medication inappropriate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00018642
|United States, California|
|VA Greater Los Angeles Healthcare System|
|Los Angeles, California, United States, 90073|
|Other Study ID Numbers:||
|First Posted:||July 5, 2001 Key Record Dates|
|Last Update Posted:||January 21, 2009|
|Last Verified:||December 2004|
Schizophrenia Spectrum and Other Psychotic Disorders
Central Nervous System Depressants
Physiological Effects of Drugs
Peripheral Nervous System Agents
Molecular Mechanisms of Pharmacological Action